Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 4, 2005, Pages 717-725

  Freeman, Jane ^a   Baines, Simon D ^a   Jabes, Daniela ^b   Wilcox, Mark H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NEeD Pharma   (Italy)

Author keywords

Antibiotic associated diarrhoea; Chemostat; Hamster

Indexed keywords

CLINDAMYCIN; CYTOTOXIN; RAMOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIUM DETECTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; FECES ANALYSIS; HAMSTER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; SPORE GERMINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CECUM; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CRICETINAE; DEPSIPEPTIDES; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GASTROINTESTINAL CONTENTS; MALE; RANDOM ALLOCATION; TIME FACTORS; VANCOMYCIN;

EID: 27144453578     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki321     Document Type: Article

References (47)

1. Bartlett JG, Moon N, Chang TW et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978; 75: 778-82.
2. George WL, Rolfe RD, Harding GK et al. Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis. Infection 1982; 10: 205-8.
3. Kelly CP, Pothoulakis C, Lamont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
4. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41 Suppl C: 21-7.
5. Freeman J, Wilcox MH. Antibiotics and Clostridium difficile. Microbes Infect 1999; 1: 777-84.
6. Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea and colitis. Johns Hopkins Med J 1981; 149: 6-9.
7. Wilcox MH. Treatment of Clostridium difficile infection. J Antimicrob Chemother 1998; 41 Suppl C: 41-6.
8. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: Response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673-9.
9. Wilcox MH, Spencer RC. Clostridium difficile infection: Responses, relapses and re-infections. J Hosp Infect 1992; 22: 85-92.
10. Citron DM, Merriam CV, Tyrell KL et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against intestinal anaerobic bactera. Antimicrob Agents Chemother 2004; 47: 2234-8.
11. Freeman J, Stott J, Baines SD et al. Surveillance for resistance to metronidazole, vancomycin and ramoplanin in genotypically distinct and clonal Clostridium difficile strains. In Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract no. E-2190, p. 216. American Society for Microbiology, Washington, DC, USA.
12. Pelaez T, Alcala L, Alonso R et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005; 49: 1157-9.
13. Panzini G, Lorenzini RN. Animal experimentation in Italy. Legislation and the authorisation of research protocols. Ann Ist Super Sanita 2004; 40: 205-10.
14. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microbiol Ecol 1998; 35: 180-7.
15. Freeman J, O'Neill FJ, Wilcox MH. The effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
16. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
17. Brown RB, Martyak SN, Barza M et al. Penetration of clindamycin phosphate into the abnormal human biliary tract. Ann Intern Med 1976; 84: 168-70.
18. Keighley MRB, Burdon DW, Arabi Y et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and post-operative diarrhoea. Br Med J 1978; 2: 1667-9.
19. Lovering AM. Lincosamide: Clindamycin and lincomycin. In: Reeves DS, Wise RW, Andrews JM, White LO, eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press, 1992; 193-8.
20. Felmingham D. Glycopeptide: Vancyomycin and teicoplanin. In: Reeves DS, Wise RW, Andrews JM, White LO, eds. Clinical Antimicrobial Assays. Oxford: Oxford University Press 1992; 37-148.
21. Patton KR, Beg A, Felmingham D et al. Determination of teicoplanin concentration in serum using a bioassay technique. Drugs Exp Clin Res 1987; 13: 547-50.
22. Impallomeni M, Galletly NP, Wort SJ et al. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. Br Med J 1995; 311: 1345-6.
23. Aronsson B, Mollby R, Nord CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: Epidemiological data from Sweden. J Infect 1985; 151: 476-81.
24. Golledge CL, McKenzie T, Riley TV. Extended spectrum cephalosporins and Clostridium difficile. J Antimicrob Chemother 1989; 23: 929-31.
25. de Lalla F, Privitera G, Ortisi G et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: A four-year survey in a general hospital. J Antimicrob Chemother 1989; 23: 623-31.
26. Settle CD, Wilcox MH, Fawley WN et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12: 1217-23.
27. Wilcox MH, Freeman J, Fawley W et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 54: 168-72.
28. Fawley WN, Freeman J, Wilcox MH. Evidence to support the existence of subclones within the UK epidemic Clostridium difficile strain (PCR ribotype I). J Hosp Infect 2003; 54: 74-7.
29. Freeman J, Wilcox MH. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2001; 47: 244-6.
30. Drummond LJ, Smith DEG, Poxton IR. Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile. J Med Microbiol 2004; 52: 1033-8.
31. Freeman J. Antibiotic related virulence factors in Clostridium difficile. 2001; PhD Thesis. University of Leeds.
32. Larson HE, Borriello SP. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother 1990; 34: 1348-53.
33. Borriello SP, Barclay FE. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol 1986; 21: 299-309.
34. Borriello SP, Ketley JM, Mitchell TJ et al. Clostridium difficile - a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis. J Med Microbiol 1987; 24: 53-64.
35. De Lalla F, Romeo B, Nicolin R et al. Oral ramoplanin (R) single-dose administration in pseudomembranous colitis (PMC). Can J Infect Dis 1995; 6 Suppl C: P452C.
36. McCafferty DG, Cudic P, Frankel BA et al. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 2002; 66: 261-84.
37. Chan WC, Dodd HM, Horn N et al. Structure-activity relationships in the peptide antibiotic nisin: Role of dehydroalanine 5. Appl Environ Microbiol 1996; 62: 2966-9.
38. Wilcox MH, Cunniffe JG, Trundle C et al. Financial burden of hospital-acquired Clostridium difficile infection. J Hosp Infect 1996; 34: 23-30.
39. O'Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991; 107: 627-35.
40. Wilcox MH, Fawley WN, Settle CD et al. Recurrence of symptoms in Clostridium difficile infection - relapse or reinfection? J Hosp Infect 1998; 38: 93-100.
41. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis 2002; 8: 802-7.
42. Poduval RD, Kamath RP, Corpuz M et al. Clostridium difficile and vancomycin-resistant enterococcus: The new nosocomial alliance. Am J Gastroenterol 2000; 95: 3513-5.
43. Carmeli Y, Eliopoulos G, Mozaffari E et al. Health and economic outcomes of vancomycin-resistant enterococci. Ann Intern Med 2002; 162: 2223-8.
44. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis 1997; 25 Suppl 2: S206-10.
45. Wong MT, Kauffman CA, Standiford HC et al. and the Ramoplanin VRE2 Clinical Study Group. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis 2001; 33: 1476-82.
46. Stiefel U, Pultz NJ, Helfand MS et al. Efficacy of oral ramoplanin for inhibition of intestinal colonisation by vancomyin-resistant enterococci in mice. Antimicrob Agents Chemother 2004; 48: 2144-8.
47. Baden LR, Critchley IA, Sahm DF et al. Molecular characterisation of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin. J Clin Microbiol 2002; 40: 1160-3.